Hansa Medical

Interim report January – March 2015

Important initiatives for future growth

January – March 2015 in brief

- Net sales in the group amounted to KSEK 3,847, compared to KSEK 1,612 for the same period 2014
- Consolidated net result was KSEK -10,725 (-5,998)
- Operating result was KSEK -10,689 (5,896)
- Earnings per share before and after dilution was SEK -0.41 (-0.26)
- Phase II clinical study of IdeS successfully completed in highly sensitized dialysis patients awaiting kidney transplantation
- Göran Arvidson appointed CFO and thereafter acting CEO
- Cooperation initiated with leading US transplantation expert Dr Stanley Jordan at Cedars-Sinai Medical Center, Los Angeles
- Development of a new generation of IdeS molecules for repeat dosing initiated
- Preliminary application for listing on Nasdaq Stockholm submitted

Significant events after the reporting period

- Fully guaranteed MSEK 246 rights issue successfully concluded

Summary of key figures

	Q1		Year
Thousands of SEK	2015	2014	2014
Net sales	3,847	1,612	4,716
Operating profit/loss	-10,689	-5,896	-24,709
Net profit/loss	-10,725	-5,998	-29,042
Earnings per share after dilution (SEK)	-0.41	-0.26	-1.16
Shareholder´s equity	39,514	37,562	49,804
Cash flow from operating activities	-7,862	-2,779	-23,623
Liquidity and other short term investments	-7,082		10,152

"In the first quarter of 2015, we took important steps, both financially and in clinical development, to build a foundation for a strong Hansa Medical."

Göran Arvidson, CFO and acting CEO

For more information, please contact:
Göran Arvidson, CFO and acting CEO
Mobile: +46 706-33 30 42
E-mail: goran.arvidson@hansamedical.com

CEO Comments

The first three months gave us a good start to the year, and we took important steps – both financially and in clinical development – to build a foundation for a strong Hansa Medical. The goal for Hansa Medical is to become a pharmaceutical company with important, life-saving products on the market. We are not there yet, and as everybody who follows the life science sector knows, you need patience to take clinical projects to the market as well as committed investors who believe in the company along the way.

Our shareholders showed us this trust when they backed our MSEK 246 rights issue that was announced in February, fully guaranteed by subscription undertakings and underwriting. The proceeds will be used to further strengthen our programme around the lead product IdeS, as well as evaluating opportunities for our other enzyme EndoS. This is an important undertaking that confirms that the shareholders also share our belief in our exciting R&D strategy.

In conjunction with the rights issue, we also announced that the estate of Bo Håkansson, Farstorps Gård AB, sold shares representing about 15 percent of the total number of shares and votes outstanding in the company. The shares were acquired by a selected number of Swedish and international institutional investors, including Rhenman & Partners and Hjärt-Lungfonden.

Our primary focus is on the lead product and value driver IdeS, a bacterial enzyme that cleaves human IgG antibodies and is considered to have great potential in kidney transplantation and rare autoimmune diseases. IdeS is currently in Phase II clinical development. In January, we announced preliminary data showing that IdeS has good efficacy in highly sensitized dialysis patients awaiting kidney transplantation. The study shows that IdeS has the capacity to make these patients eligible for transplantation by decreasing HLA antibodies to acceptable levels. Results from this study will be published in a well reputable journal.

Plans are in place to start the next Phase II study of IdeS in renal transplantation at Uppsala University Hospital, and Karolinska University Hospital in Stockholm. We also believe that IdeS has other potential medical indications, including relatively rare and serious – even life-threatening – acute immune diseases, such as anti-GBM and Guillain-Barré syndrome.

At the same time, we are developing a new generation of molecules based on IdeS allowing repeat dosing and thereby broadening the therapeutic opportunities for chronic diseases. A number of promising candidates will be optimized in 2015 in order to select a lead candidate and start preclinical development in 2016.

Our development partner Axis-Shield Diagnostics continues to further validate and market HBP-assay for prediction and diagnosis of severe sepsis world wide. In February, Axis-Shield entered a sublicense agreement for the Chinese market.

Taken all together, I believe that the first quarter clearly showed that we are in a good position – and have the means – to continue the journey to reach our goals.

Göran Arvidson
CFO and acting CEO

Company profile

Hansa Medical is a biopharmaceutical company focused on novel immunomodulatory enzymes. Its lead project IdeS is an antibody-degrading enzyme in Phase II clinical development, with potential use in transplantation and rare autoimmune diseases. Other projects include HBP (a market-launched diagnostic marker for severe sepsis) and EndoS (an antibody-modulating bacterial enzyme in pre-clinical development). The company is based in Lund, Sweden. Hansa Medical's share (HMED) is listed on Nasdaq First North in Stockholm, with Remium Nordic AB as Certified Adviser.

On February 12, 2015, the company announced that it has applied for listing of its shares on the main market of Nasdaq Stockholm.

Product development

Pharmaceutical candidate IdeS

IdeS, a unique molecule with a novel mechanism, is a bacterial enzyme that cleaves human IgG antibodies. IdeS degrades all IgG specifically, swiftly and efficiently. IdeS has been tested for safety and efficacy in numerous *in vitro* and *in vivo* models. During 2013, a Phase I clinical trial in 29 healthy subjects demonstrated that IdeS is efficacious and well tolerated, with a favourable safety profile. During 2014 and 2015, a Phase II clinical trial was conducted in sensitized patients awaiting kidney transplantation.

Transplantation

On January 20, 2015, Hansa Medical announced preliminary data from the first Phase II clinical study showing that IdeS has very good efficacy in highly sensitized patients on the kidney transplant waiting list. The study shows that IdeS has the capacity to make sensitized patients eligible for transplantation by decreasing HLA antibodies to levels acceptable for transplantation.

The database of the full study will be closed in late April and result subsequently announced.

A Phase IIb clinical study is planned for initiation in the second quarter at Uppsala University Hospital, and Karolinska University Hospital in Stockholm, to study the safety, tolerability and efficacy of reducing HLA antibody levels of IdeS in patients undergoing kidney transplantion.

On February 5, 2015, Hansa Medical initiated a collaboration with the US transplantation expert Dr Stanley Jordan. Dr Jordan is Director of Kidney Transplantation and Transplant Immunology, Kidney and Pancreas Transplant Center and Director of Division of Pediatric and Adult Nephrology at Cedars Sinai Medical Center, Los Angeles.

Dr Jordan will be scientific and medical advisor to the company, and will assist in the clinical development of IdeS in transplantation. He will also be the chairman of the Hansa Medical US Advisory Board in transplantation. An IND for an investigator-sponsored study of IdeS has been submitted and a Letter to Proceed has been received from the US Food and Drug Administration (FDA).

Other indications

IdeS has other potential medical applications. These include relatively rare and serious, or even life-threatening, acute autoimmune diseases such as Guillain-Barré syndrome and anti-GBM (Goodpasture syndrome). IdeS may also be used to degrade IgG in order to enable other forms of treatment that have lost their effect due to anti-drug antibody formation.

Second-generation IdeS molecules

On February 12, 2015, the company announced the planned development of a new generation of molecules based on IdeS that will have the potential of repeat dosing and thereby broadening the therapeutic opportunities into more chronic disease areas.

Since IdeS is a bacterial protein from Group A streptococcus, the human immune system recognises IdeS as foreign and reacts against the molecule. Hansa Medical's Phase I clinical study of IdeS demonstrated that anti-drug antibodies developed shortly after dosing. The antibodies reached peak levels two to four weeks after dosing and were normalised within 6-12 months.

The new generation IdeS molecules will have reduced anti-drug antibody binding, reduced immunogenicity and increased specific activity. Hansa Medical has patent protected the new molecules.

During 2015 and 2016, Hansa Medical intends to further optimise the new generation of molecules and select a lead candidate for pre-clinical and clinical development.

The EndoS research project

EndoS is an enzyme that modifies the glycosylation (sugar structure) of antibodies. By modifying the sugar structure, EndoS can inhibit and modify the effect of antibodies without completely eliminating them. This mechanism has several potential medical applications.
Together with academic research teams, Hansa Medical conducts research to find new treatment methods of rare but serious autoimmune diseases based on EndoS.

Diagnostic method HBP-assay

HBP-assay is a market-launched diagnostic method for predicting severe sepsis at emergency wards. In December 2012, Hansa Medical's partner, Axis-Shield Diagnostics, launched a CE-marked version of the assay. The cooperation agreement with Axis-Shield entitles Hansa Medical to receive payments from Axis-Shield, based on sub-licenses and sales.

Axis-Shield has launched a first version of the assay primarily suited for clinical specialists and clinical investigations. Axis-Shield is currently developing the assay further with the ambition of incorporating it into a faster and more accessible analysis platform. Axis-Shield Diagnostics continues to further validate and market HBP-assay for prediction and diagnosis of severe sepsis world wide. In February 2015 Axis-Shield entered a sub-license agreement for the Chinese market with Hangzhou Joinstar Biomedical Technology Co Ltd for the commercialization of an HBP-assay in China. Hansa Medical is entitled to royalties from license fees paid to Axis-Shield from sublicensees and the Chinese market is of great importance with an estimated 20-30 million cases of sepsis annually in China.

Financial report, January 1 – March 31, 2015

Net sales and profit

Net sales for the first quarter 2015 amounted to KSEK 3,847 compared with KSEK 1,612 for the corresponding period 2014. The increase is attributable to increased revenues from the partnership with Axis-Shield and comprised of licensing and royalty income from Axis-Shield.

Operating result for the first quarter 2015 amounted to KSEK –10,689 compared with an operating result of KSEK –5,896 for the corresponding period 2014. Operating result was negatively impacted by increased activity level together with the continued expansion of the organization, but also cost for the planned listing on Nasdaq OMX and transition to IFRS.

Net profit/loss for the first quarter 2015 amounted to KSEK -10,725 compared with KSEK -5,998 for the corresponding period 2014.

Cash flow and financial position

Cash flow from operating activities for the first quarter 2015 amounted to KSEK –7,862 com- pared with KSEK -2,779 for the corresponding period 2014. On March 31, 2015, cash and cash equivalents amounted to KSEK 7,082 compared with KSEK 10,152 at the end of 2014. On March 31, 2015, equity amounted to KSEK 39,514 compared with KSEK 49,804 at the end of 2014.

Investments

Investments for the first quarter 2015 amounted to KSEK 199 compared with KSEK 60 for the corresponding period 2014.

Financing

On February 23, 2015, The Board of Hansa Medical decided on a rights issue that provide the company with SEK 246 million before deduction of costs. The rights issue was fully guaranteed by subscription undertakings and underwriting.

The rights issue comprises 6,482,400 new shares with pre-emptive rights for current shareholders to subscribe for new shares at a subscription price of SEK 38 per share. The issue provide Hansa Medical with approx. SEK 246 million before deduction of issue related costs. Its principal shareholder Nexttobe AB committed to subscribe and pay for its *pro rata* share of the rights issue.

The proceeds from the issue will be used for financing pivotal development activities regarding IdeS, preclinical development of second generation IdeS and evaluate development opportunities for EndoS.

On February 2, 2015, the company took up a 20 MSEK loan facility from the principal shareholder Nexttobe AB, of which 5 MSEK was drawn during the period. In connection with the rights issue, the loan was repaid.

Parent Company

The Parent Company's net sales for the first quarter 2015 were KSEK 3,847 compared with KSEK 1,612 for the corresponding period 2014. Result after net financial items for the Parent Company amounted to KSEK -10,283 in the first quarter 2015, compared with KSEK -5,998 for the corresponding period 2014. On March 31, 2015, liquidity amounted to KSEK 7,082 compared with KSEK 10,152 at the end of 2014.

The Parent Company's equity amounted to KSEK 39,523 as per March 31, 2015, compared with KSEK 49,806 the end of the corresponding period 2014.

Significant events after the reporting period

On April 9, 2015, the company announced that its rights issue with preferential rights was subscribed at 100 percent of which 53 percent was subscribed through preferential rights. In total 3,444,862 shares were subscribed for using preferential rights. In addition, 862,694 shares were subscribed for without preferential rights, corresponding to approx. 13 percent of the number of shares in the rights issue. The remaining part was subscribed for by the underwriters.

Other information

Employees and organisation

On January 20, 2015, the company appointed Göran Arvidson as CFO. On March 2, he was appointed acting CEO of the company.

The number of employees at the end of the first quarter 2015 was 14, compared to 8 at the end of the same period 2014.

The share

Hansa Medical's share capital as of March 31, 2015 amounted to SEK 25,929,603 divided between 25,929,603 shares. There is only one share class in the Company. At a general meeting of shareholders, each share in Hansa Medical entitles the holder to one vote, with each shareholder entitled to vote for their full holding of shares. Each share entails equal rights to participation in the Company's assets and profits and equal dividends. Existing shareholders usually have preferential rights to new share issues. A general meeting of shareholders can, however, resolve on an exception from this practice. Any changes in the rights of shareholders require the approval of a general meeting of shareholders. The terms and conditions for any changes in the rights of shareholders are equivalent to those prescribed by law. There are no restrictions placed on the transfer of shares. There are no outstanding warrants, convertible promissory notes or other financial instruments that could lead to a dilution for existing shareholders.

On February 23, 2015, The Board of Hansa Medical decided on a rights issue that will provide the company with MSEK 246 before deduction of costs. The rights issue was fully guaranteed by subscription undertakings and underwriting.

The rights issue comprised of 6,482,400 new shares with pre-emptive rights for current shareholders to subscribe for new shares at a subscription price of SEK 38 per share. The issue provides Hansa Medical with approx. SEK 246 million before deduction of issue related costs. Its principal shareholder Nexttobe AB committed to subscribe and pay for its *pro rata* share of the rights issue.

The rights issue increased the number of Hansa Medical shares with 6,482,400 shares to a total amount of 32,412,003 shares. Following the rights issue, the share capital amounts to SEK 32,412,003. Paid subscribed shares, subscribed with preferential rights, are traded under the ticker HMED BTA on Nasdaq First North until April 16, 2015, after which they are expected to be converted into shares. The newly issued shares are expected to be traded on Nasdaq First North, starting on April 20, 2015.

Ownership structure

On February 23, 2015, the company announced that the estate of Bo Håkansson, Farstorps Gård AB, previously the largest shareholder in Hansa Medical AB, had sold 3,947,368 shares in Hansa Medical, representing approx. 15 percent of the total number of shares and votes outstanding in the company to a selected number of Swedish and international institutional investors, including specialist healthcare funds Rhenman & Partners, Hjärt-Lungfonden and others.

Following the placement, Farstorps Gård AB's ownership amounts to 7,122,952 shares, representing approx. 27 percent of the total number of shares and votes outstanding in Hansa Medical AB. Farstorps Gård AB has agreed not to sell any additional Hansa Medical shares until 31 August 2015, subject to certain customary exceptions.

According to the shareholder register maintained by Euroclear Sweden AB, as of March 31, 2015, Hansa Medical had 1,917 shareholders. Information regarding shareholders and shareholdings is updated each quarter on the company's website, www.hansamedical.com.

Shareholders on 31 March 2015

Name	Number of shares	Percentage (%)
Nexttobe AB	7,555,009	29.14
Farstorps Gård AB	7,122,952	27.47
Försäkringsaktiebolaget, Avanza Pension	2,329,744	8.97
Handelsbanken Fonder AB RE JP MEL	960,526	3.70
Rhenman Healthcare Equity L/S	657,894	2.53
JP Morgan Clearing Corp	634,230	2.44
Sven Sandberg	459,578	1.77
JP Morgan Bank	423,305	1.63
BWG Holding SARL	305,000	1.17
Anja Ellesson Ljunggren	254,070	0.98
Övriga	5,179,249	19.97
Totalt	**25,929,603**	**100.00**

Financial report, January 1 – March 31, 2015

Consolidated income statement

	Q1		Year
KSEK	2015	2014	2014
Net sales	3,847	1,612	4,716
Other operating income	658		59
Total operating income	**4,505**	**1,612**	**4,775**
Raw materials and consumables		-155	-245
Other external costs	-10,839	-5,178	-17,422
Personnel expenses	-4,083	-2,136	-10,468
Amortization, depreciation and write-down of tangible and intangible fixed assets	-229	-39	-1,349
Other operating expenses	-43		
Operating result	**-10,689**	**-5,896**	**-24,709**
Financial income			42
Financial expenses	-36	-102	-4,375
Net financial income/expenses	**-36**	**-102**	**-4,333**
Result before tax	-10,725	-5,998	-29,042
Tax			
Result for the period	**-10,725**	**-5,998**	**-29,042**
Attributable to			
Parent company shareholders	-10,725	-5,998	-29,042
	-10,725	**-5,998**	**-29,042**
Earnings per share			
before dilution (SEK)	-0.41	-0.26	-1.16
after dilution (SEK)	-0.41	-0.26	-1.16

Consolidated statement of comprehensive income

	Q1		Year
KSEK	2015	2014	2014
Result for the period	-10,725	-5,998	-29,042
Other comprehensive income			
Items that have been, or may be reclassified to profit or loss for the period			
Fair value changes for the year on financial assets which can be sold	435	-1,789	-2,064
Other comprehensive income for the period	**435**	**-1,789**	**-2,064**
Total net comprehensive income	**-10,290**	**-7,787**	**-31,106**

Consolidated balance sheet

KSEK	March 31, 2015	March 31, 2014	Dec 31, 2014
ASSETS			
Fixed assets			
Intangible fixed assets	36,755	38,026	36,898
Tangible fixed assets	1,396	321	1,283
Financial fixed assets	4,615	8,592	4,180
Summa anläggningstillgångar	**42,766**	**46,939**	**42,361**
Current assets			
Tax receivable	231	143	292
Trade receivables	179		59
Prepaid expenses and accrued income	2,711	392	373
Other receivables	1,586	590	1,074
Cash and cash equivalents	7,082		10,152
Total current assets	**11,789**	**1,125**	**11,950**
TOTAL ASSETS	**54,555**	**48,064**	**54,311**
EQUITY AND LIABILITIES			
Shareholders' equity			
Share capital	25,930	22,225	25,930
Other paid in capital	33,336	1,480	33,336
Reserves	435	275	
Retained earnings including result for the year	-20,187	13,582	-9,462
Shareholders' equity attribute to parent company shareholders	**39,514**	**37,562**	**49,804**
Total shareholders' equity	**39,514**	**37,562**	**49,804**
Liabilities			
Non-current interest bearing liabilities	81	121	91
Total non-current liabilities	**81**	**121**	**91**
Current interest-bearing liabilities	5,040	3,315	39
Trade payables	4,250	3,546	1,795
Other liabilities	856	473	1,039
Accrued expenses and deferred income	4,814	3,047	1,543
Total current liabilities	**14,960**	**10,381**	**4,416**
Total liabilities	**15,041**	**10,502**	**4,507**
TOTAL EQUITY AND LIABILITIES	**54,555**	**48,064**	**54,311**
Pledged assets	114	169	128
Contingent liabilities	Inga	Inga	Inga

Consolidated statement of changes in equity

KSEK	March 31, 2015	March 31, 2014	Dec 31, 2014
Opening shareholders' equity	49,804	45,349	45,349
Net comprehensive income			
Result for the year	-10,725	-5,998	-29,042
Other comprehensive income for the year	435	-1,789	-2,064
Net comprehensive income	-10,290	-7,787	-31,106
Transactions with the group's owner			
New share issue			37,042
Expenses attributable to new share issue			-1,481
Total transactions with the group's owner	0	0	35,561
Closing shareholders' equity	39,514	37,562	49,804

Consolidated statement of cash flows

	Q1		Year
KSEK	2015	2014	2014
Operating activities			
Operating income	-10,689	-5,896	-24,709
Adjustment for items not included in cash flow	229	39	1,349
Interest received			42
Interest paid	-7	-80	-123
Income taxes paid	61	68	-81
Cash flow from opening avtivities before changes to working capital	**-10,406**	**-5,869**	**-23,522**
Cash flow from changes to working capital			
Increase (-)/Decrease (+) of trade receivables	-120		-59
Increase (-)/Decrease (+) of other operating receivables	-2,850	624	159
Increase (+)/Decrease (-) of trade payables	2,455	2,836	1,085
Increase (+)/Decrease (-) of other operating liabilities	3,059	-370	-1,286
Cash flow from the operating activities	**-7,862**	**-2,779**	**-23,623**
Investing activities			
Acquisition of tangible fixed assets	-199	-60	-1,204
Acquisition of financial assets			-115
Cash flow from investing activities	**-199**	**-60**	**-1,319**
Financing activities			
New share issue			37,042
Issue expenses			-1,481
Loans raised	5,000	2,758	
Repayment of loans			-519
Repayment of leasing liabilities	-9	-9	-38
Cash flow from financing activities	**4,991**	**2,749**	**35,004**
Net cash flow	-3,070	-90	10,062
Cash and cash equivalents, beginning of year	10,152	90	90
Cash and cash equivalents, end of period	**7,082**	**0**	**10,152**

Key ratios for the Group

	Q1		Year
KSEK	2015	2014	2014
Net sales	3,847	1,612	4,716
Operating profit/loss	-10,689	-5,896	-24,709
Result for the period	-10,725	-5,998	-29,042
Earnings per share before and after dilution (SEK)	-0.41	-0.26	-1.16
Equity for the Group	39,514	37,562	49,804
Equity ratio for the Group (%)	72.9	78.1	91.7
Capitalised development costs	36,755	38,026	36,882
Cash flow from operating activities	-7,862	-2,779	-23,623

Definitions

Equity ratio
Total equity relative to total assets

Consolidated income statement per quarter

	2015	2014				2013			
KSEK	Q1	Q4	Q3	Q2	Q1	Q4	Q3	Q2	Q1
Net sales	3,847	841	877	1,386	1,612	762	353	275	337
Capitalized work on own account									64
Other operating income	658	59							
Total operating income	**4,505**	**900**	**877**	**1,386**	**1,612**	**762**	**353**	**275**	**401**
Raw materials and consumables		-7	-68	-15	-155	-73	-132	-118	-59
Other external costs	-10,839	-4,903	-3,437	-3,904	-5,178	-2,887	-3,054	-2,723	-2,526
Personnel expenses	-4,083	-3,340	-2,737	-2,255	-2,136	-2,046	-1,843	-2,010	-1,797
Amortization, depreciation and write-down of tangible and intangible fixed assets	-229	-1,208	-56	-46	-39	-38	-38	-38	-38
Other operating expenses	-43								
Operating result	**-10,689**	**-8,558**	**-5,421**	**-4,834**	**-5,896**	**-4,282**	**-4,714**	**-4,614**	**-4,019**
Financial income		42				93			
Financial expenses	-36	-4,255	-4	-14	-102	-17	-3	-3	-3
Net financial income/expenses	**-36**	**-4,213**	**-4**	**-14**	**-102**	**76**	**-3**	**-3**	**-3**
Result before tax	-10,725	-12,771	-5,425	-4,848	-5,998	-4,206	-4,717	-4,617	-4,022
Tax									
Result for the period	**-10,725**	**-12,771**	**-5,425**	**-4,848**	**-5,998**	**-4,206**	**-4,717**	**-4,617**	**-4,022**

Parent company income statement

	Q1		Year
KSEK	2015	2014	2014
Net sales	3,847	1,612	4,716
Other operating income	658		59
Total operating income	**4,505**	**1,612**	**4,775**
Raw materials and consumables		-155	-245
Other external costs	-10,848	-5,194	-17,483
Personnel expenses	-4,083	-2,136	-10,468
Amortization, depreviation and write-down of tangible and intangible fixed assets	-215	-25	-1,294
Other operating expenses	-43		
Operating result	**-10,684**	**-5,898**	**-24,715**
Result from finicial items			
Result from participating interests in group companies			-2,398
Result from other securities and receivables which are fixed assets	435		-4,252
Other interest income and similar profit/loss items			42
Interest expenses and similar profit/loss items	-34	-100	-115
Result after financial items	**-10,283**	**-5,998**	**-31,438**
Result before taxes	-10,283	-5,998	-31,438
Taxes			
Net result	**-10,283**	**-5,998**	**-31,438**

Parent company balance sheet

KSEK	March 31, 2015	March 31, 2014	Dec 31, 2014
ASSETS			
Fixed assets			
Intangible fixed assets	36,755	38,026	36,898
Tangible fixed assets	1,282	152	1,155
Financial fixed assets	4,715	10,715	4,280
Total fixed assets	**42,752**	**48,893**	**42,333**
Current assets			
Current receivables			
Trade receivables	179		59
Tax receivable	231	143	292
Other receivables	1,586	590	1,074
Prepaid expenses and accrued income	2,711	402	373
Total current recievables	4,707	1,135	1,798
Cash and cash equivalents	7,082		10,152
Total current assets	**11,789**	**1,135**	**11,950**
TOTAL ASSETS	**54,541**	**50,028**	**54,283**
EQUITY AND LIABILITIES			
Shareholders' equity			
Restricted equity			
Share capital	25,930	22,225	25,930
Unrestricted sharholders' equity			
Share premium reserve	33,336	1,480	33,336
Retained earnings	-9,460	21,978	21,978
Net result	-10,283	-5,998	-31,438
Total shareholders' equity	**39,523**	**39,685**	**49,806**
Current liabilities			
Liabilities to credit institutions	5,000	3,277	
Trade payables	4,250	3,546	1,795
Liabilities to group companies	98		100
Other liabilities	856	473	1,039
Accrued expenses and deferred income	4,814	3,047	1,543
Total current liabilities	**15,018**	**10,343**	**4,477**
TOTAL SHAREHOLDERS' EQUITY AND LIABILITIES	**54,541**	**50,028**	**54,283**

Notes

Note 1 Accounting principles

This interim report for the Group has been prepared according to IAS 34 "Interim Financial Reporting" and the applicable provisions of the Swedish Annual Accounts Act. This interim report is the second official report in which Hansa Medical applies IFRS. A full description of the accounting principles applied in this interim report can be found in the Year-End Report 2014, which was published on February 13, 2015. It is available on www.hansamedical.com.

Note 2 Fair value for financial instruments

The reported value is assessed as being a fair approximation of the fair value for all of the Group's financial instruments. The financial instruments reported at fair value in the balance sheet are comprised solely of the Group's holding of shares in Genovis, which is listed on Nasdaq First North. The fair value of the shares as per the balance sheet date was KSEK 4,615 on March 31 2015, KSEK 8,592 on March 31 2014 and KSEK 4,180 on December 31 2014, calculated on the basis of the closing price. The valuation of the holding is, thereby, in accordance with Level 1 in the valuation hierarchy.

Legal information and financial calendar

Legal disclaimer

This financial report includes statements that are forward-looking, and actual future results may differ materially from those stated. In addition to the factors discussed, among other factors that may affect results are development within research programs, including development in preclinical and clinical trials, the impact of competing research programs, the effect of economic conditions, the effectiveness of the Company's intellectual property rights and preclusions of potential third party's intellectual property rights, technological development, exchange rate and interest rate fluctuations, and political risks.

Auditor's review

This interim report has not been subject to review by Hansa Medical's auditors.

Certified Adviser

Hansa Medical's Certified Adviser is Remium Nordic AB.

Forthcoming financial reports

Interim Report for January – June 2015	August 25, 2015
Interim Report for January – September 2015	October 28, 2015
Year-end Report 2015	February 2016

Financial reports, press releases, notices of extraordinary general meetings of shareholders and other information is available from Hansa Medical's website www.hansamedical.com from their date of publication.

Annual General Meeting

The Annual General Meeting of Hansa Medical AB (publ) will take place on June 2, 2015. The notice of the Annual General Meeting will be available on Hansa Medical's website www.hansamedical.com no later than four weeks prior to the Annual General Meeting.

Hansa Medical is obligated to publish the information contained in this interim report in accordance with the Swedish Securities Market Act. This information was provided to the media for publication on April 16, 2015 at 6:00 p.m.

Hansa Medical AB (publ)
Scheelevägen 22
SE-223 63 Lund
Sweden

Postal address:
P.O. Box 785
SE-220 07 Lund
Sweden

Registration number:
556734-5359

Glossary

Anti-GBM
Anti-GBM - or Goodpasture syndrome - is an autoimmune disease, which primarily affects kidneys and lungs.

Antibody
One type of proteins produced by the body's immune system with the ability to recognise foreign substances, bacteria or viruses. Antibodies are also called immunoglobulins.

Autoimmune disease
Diseases that occur when the body's immune system reacts against the body's own structures.

Biotechnology
The use of live cells or components of cells, to produce or modify products used in health care, food, and agriculture.

Clinical studies
Investigation of a new drug or treatment using healthy subjects or patients with the intention to study the efficacy and safety of a not-yet-approved treatment approach.

Clinical Phase I
The first time that a drug under development is administered to humans. Phase I studies are often conducted with a small number of healthy volunteers to assess the safety and dosing of a not yet approved form of treatment.

Clinical Phase II
Refers to the first time that a drug under development is administered to patients for the study of safety, dosage and efficacy of a not yet approved treatment regimen.

Clinical Phase III
Trials that involve many patients and often continues for a longer time; they are intended to identify the drug's effects and side effects during ordinary but still carefully controlled conditions.

Diagnostics
A wide range of different methods to identify diseases and medical conditions based on clinical symptoms and a variety of medical tests such as blood tests and radiology.

EndoS
A bacterial endoglycosidase of Streptococcus pyogenes. An enzyme with the unique ability to modify a specific carbohydrate chain of immunoglobulines.

Enzyme
A protein that accelerates or starts a chemical reaction without itself being consumed.

FDA
US Food and Drug Administration.

Guillain-Barré syndrome
A rare and acute autoimmune disease of the nerves where antibodies are formed mainly directed towards the insulating myelin sheath of nerves and nerve roots.

HBP
Heparin Binding Protein is a naturally occurring protein that is produced by certain immune cells, i.e. neutrophilic granulocytes, to direct immune cells from the bloodstream into the tissues.

HLA
Human Leukocyte Antigen is a protein complex found on the surface of all cells in a human. The immune system uses HLA to distinguish between endogenous and foreign.

IdeS
IdeS, immunoglobulin G-degrading enzyme of Streptococcus pyogenes, a bacterial enzyme with strict specificity for IgG antibodies. The enzyme has a unique ability to cleave and thereby inactivate human IgG antibodies.

IgG
IgG, Immunoglobulin G, is the predominant type of antibody in serum.

In vitro
Term within biomedical science to indicate that experiments or observations are made, for example in test tubes, i.e. in an artificial environment and not in a living organism.

In vivo
Term within biomedical science to indicate that experiments or observations are made on living organisms.

Milestone
Payments a company receives in accordance with a cooperation agreement after the company reaches a pre-set target, such as "proof-of-concept".

Preclinical development
Testing and documentation of a pharmaceutical candidate's properties (e.g. safety and feasibility) before initiation of clinical trials.

Sepsis
Diagnosed or suspected infection in combination with the patient is in a systemic inflammatory state (SIRS). Clinical symptoms of systemic inflammation may be a combination of fever, increased heart rate and increased respiratory rate.

Severe sepsis
Sepsis is progressing into severe sepsis when the patient may suffer circulatory effects and reduced functions of vital organs such as the brain, heart, lungs, kidneys or liver.

Streptococcus pyogenes
A Gram-positive bacterium that primarily can be found in the human upper respiratory tract. Some strains can cause throat or skin infections.

www.hansamedical.com